Advertisement
Singapore markets close in 7 hours 36 minutes

  • Straits Times Index

    3,081.36
    +8.37 (+0.27%)
     

  • Nikkei

    33,436.03
    -50.86 (-0.15%)
     

  • Hang Seng

    17,042.88
    0.00 (0.00%)
     

  • FTSE 100

    7,453.75
    +30.29 (+0.41%)
     

  • Bitcoin USD

    37,768.76
    -14.50 (-0.04%)
     

  • CMC Crypto 200

    783.32
    -0.33 (-0.04%)
     

  • S&P 500

    4,567.80
    +17.22 (+0.38%)
     

  • Dow

    35,950.89
    +520.47 (+1.47%)
     

  • Nasdaq

    14,226.22
    -32.27 (-0.23%)
     

  • Gold

    2,044.30
    +6.20 (+0.30%)
     

  • Crude Oil

    75.80
    -0.16 (-0.21%)
     

  • 10-Yr Bond

    4.3520
    +0.0810 (+1.90%)
     

  • FTSE Bursa Malaysia

    1,451.20
    -1.54 (-0.11%)
     

  • Jakarta Composite Index

    7,080.74
    +44.65 (+0.63%)
     

  • PSE Index

    6,223.73
    -41.41 (-0.66%)
     

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Business Wire
·1-min read

SOUTH SAN FRANCISCO, Calif., August 28, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230828696222/en/

Contacts

Media Contact
Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokegroup.com
media@sprucebio.com

Investors
Samir Gharib
President and CFO
Spruce Biosciences
investors@sprucebio.com